Telomir Highlights Positive Preclinical Results for Telomir-1 in TNBC

Telomir Pharmaceuticals, Inc. ( (TELO) ) just unveiled an update.

Telomir Pharmaceuticals reported results from a completed preclinical efficacy study using zebrafish tumor xenograft models of triple-negative breast cancer, in which Telomir-1 significantly reduced primary tumor growth and metastatic spread in two aggressive TNBC models, either as a monotherapy or in combination with paclitaxel, particularly in tumors representing biologically defined subtypes estimated to account for 40–60% of TNBC cases and including one model that was not responsive to paclitaxel. In contrast, Telomir-1 and paclitaxel showed no statistically significant effect in a third, broadly treatment-resistant TNBC model, which the company said underscores the biological specificity of Telomir-1’s activity and supports using underlying tumor metal regulation and epigenetic profiles to guide future indication selection, patient stratification, and clinical trial design as it continues IND-enabling work.

The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.

More about Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a biopharmaceutical company developing Telomir-1 (Zn-Telomir), a metal-modulating therapeutic candidate aimed at treating cancers such as triple-negative breast cancer (TNBC). The company focuses on leveraging differences in tumor biology, including regulation of intracellular metals and epigenetically controlled gene activity, to target specific cancer subtypes and guide patient selection strategies.

Average Trading Volume: 1,715,090

Technical Sentiment Signal: Sell

Current Market Cap: $46.07M

For detailed information about TELO stock, go to TipRanks’ Stock Analysis page.